FibroBiologics Secures European Patent Covering Methods Of Preparing Fibroblasts To Home To Tumors And Carry Oncolytic Viruses And Other Anti-Cancer Agents

HOUSTON, Nov. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Patent No. EP 4454709, titled "Fibroblast Delivery of Tumor Inhibitory Agents." The patent covers methods of preparing fibroblasts as anti-cancer delivery compositions by modifying the cells to improve their ability to home to cancer cells and loading them with one or more tumor inhibitory agents, including an oncolytic virus.